- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Do | Sanofi and Regeneron's Dupixent, Leo Pharma's Anzupgo could help close treatment gap in chronic hand eczema: GlobalData | ||
| Do | FDA reaffirms decision to erase Eli Lilly's tirzepatide from shortage list, halting future flow of knockoffs | ||
| Do | Klick Health goes on a hiring spree to close out the year, adding 22 new leaders | ||
| Do | After two rejections, FDA approves Mesoblast's first-of-its-kind cell therapy | ||
| Do | Playing catch-up with Pfizer and Roche, China-made ALK drug clears FDA in lung cancer | ||
| Do | Novartis to shutter 2 MorphoSys sites, lay off 330 staffers in post-buyout consolidation | ||
| Do | Analysts tip BMS' Cobenfy to be top dog in growing schizophrenia market | ||
| Mi | Takeda casts a new line with first DTC campaign for HyQvia in CIDP | ||
| Mi | Trio of drugmakers issue drug recalls tied to impurity, labeling issues | ||
| Mi | African Union gains $45M package to boost vaccine manufacturing in Senegal | ||
| Mi | India's ACG kicks off operations at mammoth capsule plant in Thailand | ||
| Mi | Regeneron's Eylea HD passes key test in retinal vein occlusion, teeing up 2025 FDA filing as Eylea threats mount | ||
| Di | CMI Media Group taps Anoki AI to fine-tune pharma ad targeting | ||
| Di | After studies flag possible link between Novo's Ozempic and rare eye disorder, Danish agency calls for probe | ||
| Di | Pfizer CEO says he developed 'good relation' with RFK Jr., highlights Trump's pride in vaccine work | ||
| Di | Doctors weigh in on GLP-1s: The impact of celeb endorsements, the indications they're hoping for and more | ||
| Di | Sandoz shells out $275M in latest effort to move past 'legacy' price-fixing litigation | ||
| Di | Cozadd's coda: Jazz unveils succession plan as longtime CEO and co-founder plots retirement | ||
| Di | Pfizer expects $1B hit from IRA's Part D redesign and no major M&A in 2025 | ||
| Di | FDA rejects J&J's subcutaneous Rybrevant filing and AstraZeneca's full approval bid for Andexxa | ||
| Mo | Novo Holdings set to close $16.5B Catalent buy in 'coming days' after deal clears antitrust hurdles | ||
| Mo | Neurocrine's Crenessity ends 70-year drought with FDA nod for rare genetic disease | ||
| Mo | Checkpoint Therapeutics takes on Merck's mighty Keytruda with FDA approval for Unloxcyt in skin cancer | ||
| Mo | Novo Nordisk blueprints $1.2B rare disease production plant in Denmark, where it plans to hire on 400 new staffers | ||
| Mo | Bavarian Nordic inks mpox vaccine pact with Serum Institute of India, expands global reach of the shot |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
